专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009135799A3 METHOD FOR EVALUATING THE SOLUBILITY OF A CRYSTALLINE SUBSTANCE IN A POLYMER 审中-公开
标题翻译：评估聚合物中晶体物质的溶解性的方法
公开(公告)号：WO2009135799A3
公开(公告)日：2010-01-28
申请号：PCT/EP2009055233
申请日：2009-04-29
申请人： ABBOTT GMBH & CO KG , ZHANG GEOFF G Z , YU LIAN , TAO JING , SUN YE , MAEGERLEIN MARKUS
发明人： ZHANG GEOFF G Z , YU LIAN , TAO JING , SUN YE , MAEGERLEIN MARKUS
IPC分类号： G01N33/15 , G01N25/48
CPC分类号： G01N33/15 , G01N25/4866
摘要： A viable strategy to enhance the bioavailability of poorly soluble drugs is to use amorphous solids in place of the more commonly used crystalline solids in pharmaceutical formulations. However, amorphous solids are physically meta-stable and tend to revert back to their crystalline counterpart. An effective approach to stabilizing an amorphous drug against crystallization is to disperse it in a polymer matrix. The drug's solubility in the chosen polymer defines the upper limit of drug loading without any risk of crystallization. Measuring the solubility of a drug in a polymer has been a scientific and technological challenge because the high viscosity of polymers makes achieving solubility equilibrium difficult and because pharmaceutically important drug/polymer dispersions are glasses, which undergo structural relaxation over time. The invention provides a method based on Differential Scanning Calorimetry (DSC) for measuring the solubility of crystalline drugs in polymeric matrices. The method relies on the detection of the dissolution endpoint of a drug/polymer mixture prepared by cryomilling.
摘要翻译：提高难溶性药物的生物利用度的可行策略是使用无定形固体代替药物制剂中更常用的结晶固体。然而，无定形固体物理上是元稳定的，并且倾向于回复到它们的结晶对应物。稳定无定形药物抗结晶的有效方法是将其分散在聚合物基质中。药物在所选聚合物中的溶解度限定了药物负载的上限，而没有结晶的风险。测量药物在聚合物中的溶解度已经是科学和技术挑战，因为聚合物的高粘度使得难以实现溶解度平衡，并且因为药物重要的药物/聚合物分散体是随时间经历结构松弛的玻璃。本发明提供了一种基于差示扫描量热法（DSC）测量结晶药物在聚合物基质中的溶解度的方法。该方法依赖于通过冷冻法制备的药物/聚合物混合物的溶解终点的检测。

2. 发明申请

WO2011156464A8 CRYSTALLINE FORMS OF KINASE INHIBITORS 审中-公开
标题翻译：激酶抑制剂的晶体形式
公开(公告)号：WO2011156464A8
公开(公告)日：2012-10-11
申请号：PCT/US2011039591
申请日：2011-06-08
申请人： ABBVIE INC , HOFFMAN DOUG H , MILLER JONATHAN , ZHANG GEOFF G Z
发明人： HOFFMAN DOUG H , MILLER JONATHAN , ZHANG GEOFF G Z
IPC分类号： C07D495/04 , A61K31/4365 , A61P35/00
CPC分类号： C07D495/04
摘要： Citrate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
摘要翻译：噻吩并[3,2-c]吡啶-3-基}苯基）-N（4- {4-氨基-7- [1-（2-羟乙基）-1H-吡唑-4-基] ' - （3-氟苯基）脲及其结晶形式是用于治疗疾病例如癌症的药物组合物的合适的药物成分。

3. 发明申请

WO2008058096A3 AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS 审中-公开
标题翻译：亚胺丹衍生物及其作为NICOTINIC乙酰胆碱受体配体使用
公开(公告)号：WO2008058096A3
公开(公告)日：2008-08-07
申请号：PCT/US2007083687
申请日：2007-11-06
申请人： ABBOTT LAB , SCHRIMPF MICHAEL R , NERSESIAN DIANA L , SIPPY KEVIN B , JI JIANGUO , LI TAO , SCANIO MARC , SHI LEI , LEE CHIH-HUNG , BUNNELLE WILLAIM H , ZHANG GEOFF G Z , BRACKEMEYER PAUL J , CHEN SHUANG , HENRY RODGER F
发明人： SCHRIMPF MICHAEL R , NERSESIAN DIANA L , SIPPY KEVIN B , JI JIANGUO , LI TAO , SCANIO MARC , SHI LEI , LEE CHIH-HUNG , BUNNELLE WILLAIM H , ZHANG GEOFF G Z , BRACKEMEYER PAUL J , CHEN SHUANG , HENRY RODGER F
IPC分类号： C07D451/14 , A61K31/395
CPC分类号： C07D471/18 , A61K31/095 , A61K31/439 , A61K31/444 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , C07C309/29 , C07D451/14 , C07D471/08 , C07F5/022
摘要： The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine -substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.
摘要翻译：本发明涉及作为式（I）的氮杂金刚烷衍生物的化合物，特别是醚或胺取代的氮杂金刚烷衍生物及其盐和前药，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法和在此过程中获得的中间体。

4. 发明申请

WO2008058096A9 AZAADAMANTANE DERIVATIVES AND METHODS OF USE 审中-公开
标题翻译：亚胺丹衍生物及其使用方法
公开(公告)号：WO2008058096A9
公开(公告)日：2008-06-26
申请号：PCT/US2007083687
申请日：2007-11-06
申请人： ABBOTT LAB , SCHRIMPF MICHAEL R , NERSESIAN DIANA L , SIPPY KEVIN B , JI JIANGUO , LI TAO , SCANIO MARC , SHI LEI , LEE CHIH-HUNG , BUNNELLE WILLAIM H , ZHANG GEOFF G Z , BRACKEMEYER PAUL J , CHEN SHUANG , HENRY RODGER F
发明人： SCHRIMPF MICHAEL R , NERSESIAN DIANA L , SIPPY KEVIN B , JI JIANGUO , LI TAO , SCANIO MARC , SHI LEI , LEE CHIH-HUNG , BUNNELLE WILLAIM H , ZHANG GEOFF G Z , BRACKEMEYER PAUL J , CHEN SHUANG , HENRY RODGER F
IPC分类号： C07D451/14 , A61K31/395
CPC分类号： C07D471/18 , A61K31/095 , A61K31/439 , A61K31/444 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , C07C309/29 , C07D451/14 , C07D471/08 , C07F5/022
摘要： The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.
摘要翻译：本发明涉及作为氮杂金刚烷衍生物的化合物，特别是醚取代或胺取代的氮杂金刚烷衍生物及其盐和前体药物，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法以及在此过程中获得的中间体。

5. 发明申请

WO2007100990A2 OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES 审中-公开
标题翻译： OCTAHYDRO-PYRROLO [3,4-B]吡咯烷酮衍生物
公开(公告)号：WO2007100990A2
公开(公告)日：2007-09-07
申请号：PCT/US2007062329
申请日：2007-02-16
申请人： ABBOTT LAB , COWART MARLON D , ZHAO CHEN , SUN MINGHUA , BLACK LAWRENCE A , ZHENG GUO ZHU , GREGG ROBERT J , ZHANG GEOFF G Z , SHEIKH AHMAD Y , LOU XIAOCHUN , HENRY RODGER F , BARNES DAVID M , KOLACZKOWSKI LAWRENCE , HAIGHT ANTHONY R , CHANG SOU-JEN , WITTENBERGER STEVEN J , FICKES MICHAEL G
发明人： COWART MARLON D , ZHAO CHEN , SUN MINGHUA , BLACK LAWRENCE A , ZHENG GUO ZHU , GREGG ROBERT J , ZHANG GEOFF G Z , SHEIKH AHMAD Y , LOU XIAOCHUN , HENRY RODGER F , BARNES DAVID M , KOLACZKOWSKI LAWRENCE , HAIGHT ANTHONY R , CHANG SOU-JEN , WITTENBERGER STEVEN J , FICKES MICHAEL G
IPC分类号： C07D487/04 , A61K31/407
CPC分类号： C07D487/04
摘要： Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
摘要翻译：八氢吡咯并[3,4-b]吡咯衍生物可用于治疗组胺-3受体配体预防或改善的病症或病症。八氢吡咯并[3,4-b]吡咯化合物，使用这些化合物的方法，制备它们的组合物和制备这些化合物的方法在本文中公开。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式